Detalle Publicación


Depletion of alloreactive T-cells in vitro using the proteasome inhibitor bortezomib preserves the immune response against pathogens

Autores: Blanco B; Sánchez-Abarca LI; Caballero-Velázquez T; Santamaría C; Inoges Sancho, Susana Inmaculada; Pérez-Simón JA
Título de la revista: LEUKEMIA RESEARCH
ISSN: 0145-2126
Volumen: 35
Número: 10
Páginas: 4012-15
Fecha de publicación: 2011
Current graft-versus-host disease (GVHD) inhibition approaches lead to abrogation of pathogen-specific T-cell responses. We propose an approach to inhibit GVHD without hampering immunity against pathogens: in vitro depletion of alloreactive T cells with the preoteasome inhibitor bortezomib. We show that PBMCs stimulated with allogeneic cells and treated with bortezomib greatly reduce their ability to produce IFN-¿ when re-stimulated with the same allogeneic cells, but mainly preserve their ability to respond to citomegalovirus stimulation. Unlike in vivo administration of immunosuppressive drugs or other strategies of allodepletion, in vitro allodepletion with bortezomib maintains pathogen-specific T cells, representing a promising alternative for GVHD prophylaxi